There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT2A serotonin receptor. Here, we present 7 cryo-EM structures covering all major compound...
Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic in depression and suicidal ideations, could be an innovative adjuvant treatment for the AN spectrum. We describe a case series...
In recent years, there has been a significant surge of interest in psychedelic research. These studies encompass both neuroscience and their potential clinical applications. This phenomenon, often referred to as the "Psychedelic Renaissance", includes studies on compounds such as psilocybin, MDMA, DMT, and LSD used for the treatment of depression, post-traumatic stress disorder, anxiety, and...
Recent clinical trials on classic psychedelics for depression and anxiety have raised questions about their potential to treat other psychiatric conditions. Evidence from pre-clinical and clinical research suggests psychedelics may help with substance use disorders, with ongoing registered trials. Behavioral addictions, sharing features with substance addictions, may also respond to psychedelic...
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as a recreational drug, may also offer therapeutic benefits for mental health. Population-based studies suggest that MDMA users have a lower risk of demyelinating diseases, such as depression. Given the role of the gut microbiota in mediating MDMA's effects, we hypothesized that MDMA might confer mental health benefits via the gut-brain...
Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic...
Long COVID lacks effective pharmaceutical treatment options. Psychedelic treatment for long COVID has received attention given anecdotal reports of neuropsychiatric symptom improvement. This study investigates the use of psilocybin for neuropsychiatric long COVID symptoms, examining online accounts of individuals with reported long COVID using psilocybin. We searched the Reddit communities,...
IGI Global eBooksMarch 13, 2025K.Suresh Kumar, Sandeep Kumar Davuluri, Lakshman Kumar Kanulla et al.2 citations
Historical stories and contemporary clinical studies have shown substantial promise for the therapeutic use of psychedelics for the treatment of mood disorders such as depression. Comp360 is COMPASS Pathways' unique synthetic formulation of psilocybin. A recent randomised double-blind phase-II b research showed that it was safe and effective for those with treatment-resistant depression. The...
This review aims to evaluate the effectiveness of mindfulness-based interventions in improving the mental health of parents of children with intellectual and developmental disabilities (IDDs), specifically focusing on outcomes such as parental stress, anxiety, depression, and parent-child relationships. A systematic search was conducted across multiple databases, including Web of Science,...
CirculationMarch 11, 2025Andrea Lopez, S. Suglia, Tené Lewis et al.
Background: Young women in Puerto Rico (PR) experience a high burden of psychological distress, a non-traditional risk factor for cardiovascular disease. Mindfulness practice may help reduce psychological distress and improve health behaviors, benefiting cardiovascular health. However, conventional 8-week mindfulness-based stress reduction (MBSR) programs’ time requirements and in-person format...